

49. Hartman TR, Nicolas E, Klein-Szanto A, et al. The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis. *Oncogene* 2009; 28(13): 1594–1604.
50. Maher ER. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. *World J Urol.* 2018; 36(12): 1891–1898.
51. Křepelová A, Puchmajerová A, Vasovčák P, ChochoLATÝ M. Birt-Hogg-Dubé syndrome. *Klin Onkol.* 2012; 25(Suppl): S18–20.
52. Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg-Dubé syndrome. *Am J Surg Pathol.* 2002; 26(12): 1542–1552.
53. He H, Trpkov K, Martinek P, et al. „High-grade oncocytic renal tumor“: morphologic, immunohistochemical, and molecular genetic study of 14 cases. *Virchows Arch.* 2018; 473(6): 725–738.
54. Stamatakis L, Metwalli AR, Middleton LA, Marston Linehan W. Diagnosis and management of BHD-associated kidney cancer. *Fam Cancer* 2013; 12(3): 397–402.
55. Musil Z, Vícha A, Zelinka T, et al. Hereditary pheochromocytoma and paraganglioma. *Klin Onkol.* 2012; 25 Suppl: S21–26.
56. Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. *J Natl Cancer Inst.* 2008; 100(17): 1260–1262.
57. Kuroda N, Yorita K, Nagasaki M, et al. Review of succinate dehydrogenase-deficient renal cell carcinoma with focus on clinical and pathobiological aspects. *Pol J Pathol.* 2016; 67(1): 3–7.
58. Gill AJ, Hes O, Papathomas T, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. *Am J Surg Pathol.* 2014; 38(12): 1588–1602.
59. Rednam SP, Erez A, Druker H, et al. Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. *Clin Cancer Res.* 2017; 23(12): e68–e75.
60. Mester JL, Zhou M, Prescott N, Eng C. Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndrome. *Urology.* 2012; 79(5): 1187.e1–7.
61. Farley MN, Schmidt LS, Mester JL, et al. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. *Mol Cancer Res.* 2013; 11(9): 1061–1071.
62. Popova T, Hebert L, Jacquemin V, et al. Germline BAP1 mutations predispose to renal cell carcinomas. *Am J Hum Genet.* 2013; 92(6): 974–980.
63. Chen JD, Morrison C, Zhang C, et al. Hyperparathyroidism-jaw tumour syndrome. *J Intern Med.* 2003; 253(6): 634–642.
64. Hora M, Hes O, Eret V, et al. Translokační renální karcinom Xp11.2 typu ASPL/TFE3. *Ces Urol* 2008; 12(3): 186–193.